医学
多发性骨髓瘤
吡格列酮
内科学
二甲双胍
不利影响
糖尿病
疾病
癌症
恶性肿瘤
肾病
肿瘤科
内分泌学
2型糖尿病
作者
Anastasios Tentolouris,Ioannis Ntanasis‐Stathopoulos,Ioanna Eleftheriadou,Panagiotis Malandrakis,Evangelia Tzeravini,Maria Gavriatopoulou
摘要
Diabetes mellitus (DM) has attained the status of a global pandemic. Cardiovascular disease (CV) was the leading cause of morbidity in people with type 2 DM, however, a transition from CV to cancer as the leading contributor to DM related death has been observed lately. Multiple myeloma (MM) is the second most common haematological malignancy. Obesity is a common risk factor for both DM and MM. Although data are limited, studies have shown that DM might be associated with increased risk for the development of MM. The presence of DM might affect the course of patients with MM, since hyperglycemia may have an impact on both the efficacy and the adverse effects of antimyeloma therapy. In parallel, DM and MM share common clinical presentations, such as nephropathy, neuropathy, and CV. In terms of antidiabetic medications, metformin might present a synergistic effect with antimyeloma drugs and also prevent some of the adverse effects of these drugs; pioglitazone might have favourable effects when given as add on treatment in people with relapsed or refractory MM. No clinically important interactions have been observed between antidiabetic agents and the most commonly used antimyeloma drugs. Further data are needed to examine the effect of all classes of antidiabetic medication on MM and its complications. A baseline assessment of risk factors for glucose intolerance and close monitoring of glucose levels during therapy is strongly suggested for patients with MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI